Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Presentation source : Www.beyondspringpharma.com save search
BeyondSpring Announces Late-Breaking Oral Presentation of Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination Versus Docetaxel Alone in 2nd/3rd Line Non-Small Cell Lung Cancer Patients with EGFR Wild Type at the European Society for Medical Oncology 2021 Congress
Published: 2021-08-31 (Crawled : 15:00) - beyondspringpharma.com
BYSI | $1.8 -2.21% 80K
|
Health Technology
|
| O: 0.25%
H: 19.31%
C: 13.2%
presentation lung cancer europe cancer phase 3 plinabulin
BeyondSpring Announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data Showing Plinabulin, in Combination with Pegfilgrastim, Reverses the Immune-Suppressive Effects of Pegfilgrastim and Offers Superior Prevention of Chemotherapy-Induced Neutropenia (CIN) at the FOCIS Annual Meeting
Published: 2021-06-08 (Crawled : 13:00) - beyondspringpharma.com
BYSI | $1.8 -2.21% 80K
|
Health Technology
|
| O: 1.07%
H: 0.64%
C: -5.31%
presentation therapy phase 3 plinabulin
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.